• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Bristol-Myers Squibb

edit

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products.

The company operates in two segments, Pharmaceuticals and Nutritionals. The Nutritionals segment is operated through the company’s subsidiary Mead Johnson Nutrition Company (Mead Johnson). Pharmaceuticals Segment The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Milestones

edit

• 
  Bristol-Myers Squibb invested in XDx. (10/7/09)
  Posted 10/7/09 at 3:26pm via onbiovc.com
• 
  Bristol-Myers Squibb invested in XDx. (8/5/09)
  Posted 9/24/09 at 1:47pm via bizjournals.com
• 
  Bristol-Myers Squibb acquired Amira Pharmaceuticals for $325M. (7/21/11)
  Posted 7/22/11 at 5:19am via businesswire.com
• 
  Bristol-Myers Squibb acquired Kosan Biosciences for $338M. (5/28/08)
  Posted 9/13/09 at 5:36pm
• 
  Bristol-Myers Squibb acquired Medarex for $2.1B. (7/27/09)
  Posted 7/28/09 at 3:08pm via foxbusiness.com

Videos

Screenshots

edit

Above: Bristol-Myers Squibb Screenshot -- #1
Uploaded: 8/28/09

Sources

1. Bristol-Myers Squibb to Acquire Amira Pharmaceuticals (businesswire.com) [edit]
2. Bristol-Myers Squibb to Acquire Medarex (foxbusiness.com) [edit]
3. Cap Funding Report [edit]
4. XDx, Inc.: Series G $14.4M (onbiovc.com) [edit]
5. XDx raises $14.4M new funding (sanjose.bizjournals.com) [edit]